Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.85 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.85 |
| ▸ | ME2 | P23368 | 1/20 | 0.67 |
| ▸ | ME1 | P48163 | 1/20 | 0.67 |
| ▸ | ME3 | Q16798 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | GALK1 | P51570 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL5379175 | 0.94 | GPR35 (0.91) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL15955719 | 0.94 | GPR35 (0.91) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL29362189 | 0.92 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL446833 | 0.92 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293206 | 0.92 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5721 | 0.92 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293211 | 0.92 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL8694068 | 0.91 | POLB (0.85) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL1055608 | 0.91 | GPR35 (0.97) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014030 | 0.91 | GPR35 (0.97) | POLBGPR35ME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340637-A1 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES | BEND RESEARCH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9737538-B2 | Solid dispersions of low-water solubility actives | BEND RESEARCH, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170209375-A1 | NANOPARTICLE FORMULATIONS OF LOW-WATER SOLUBILITY ACTIVES | BEND RESEARCH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9622995-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | disclosed |
| US-9408887-B2 | Intermittent dosing regimen for treating breast cancer | NEW YORK UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150374827-A1 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES | BEND RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | NATIONAL INSTITUTES OF HEALTH | 2015-09-24 | — | — | US | disclosed |
| US-9040583-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150099700-A1 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-20150045545-A1 | SORBENT COMPRISING ON ITS SURFACE AN AROMATIC RING SYSTEM HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | INSTRACTION GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8835123-B2 | Methods for detecting progenitor cells and uses thereof | NEW YORK UNIVERSITY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8420648-B2 | Polymorphs of brimonidine pamoate | BAUSCH & LOMB INCORPORATED (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013037992-A1 | SORBENT COMPRISING ON ITS SURFACE AN AROMATIC RING SYSTEM HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | INSTRACTION GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| EP-2570184-A1 | Sorbent comprising on its surface an aromatic ring system having an anionic or deprotonizable group for the purification of organic molecules | InstrAction GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130058950-A1 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-03-07 | — | — | US | disclosed |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209375-A1 | NANOPARTICLE FORMULATIONS OF LOW-WATER SOLUBILITY ACTIVES | ACP1, AQP1, AQP3 | POLB 1305/4885GPR35 3825/4885ME2 3044/4885 |
| US-20150045545-A1 | SORBENT COMPRISING ON ITS SURFACE AN AROMATIC RING SYSTEM HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | ABCG2, SORBS1, MAOA | POLB 1460/4885GPR35 779/4885ME2 1739/4885 |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | POLB 4617/4885GPR35 1/4885ME2 2603/4885 |
| US-20150374827-A1 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES | ABCG2, AQP3, SLC26A3 | POLB 431/4885GPR35 4447/4885ME2 4168/4885 |
| US-20170340637-A1 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES | ABCG2, AQP3, SLC26A3 | POLB 431/4885GPR35 4447/4885ME2 4168/4885 |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | POLB 4617/4885GPR35 1/4885ME2 2603/4885 |
| US-20130058950-A1 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF | BRCA1, TP53, PGR | POLB 4079/4885GPR35 1988/4885ME2 4152/4885 |
| US-20150099700-A1 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF | BRCA1, TP53, PGR | POLB 4079/4885GPR35 1988/4885ME2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.